We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Should Tilray Brands Be in Your Portfolio Post Q3 Earnings?
Read MoreHide Full Article
Key Takeaways
Tilray posted Q3 revenue growth of 11% but missed earnings estimates despite improving year over year.
Tilray's distribution and cannabis segments drove growth, with global cannabis revenue up 41%.
TLRY faces rising competition and pricing pressure, with beverage weakness weighing on overall performance.
On Wednesday, Tilray Brands (TLRY - Free Report) reported mixed third-quarter results for fiscal 2026 (year ending May 2026), with revenues beating estimates but earnings missing expectations. Both numbers improved when compared to the year-ago quarter.
Tilray posted a loss per share of 24 cents, a 97% improvement from the year-ago quarter, which had been significantly impacted by a $699.2 million impairment charge. Excluding this one-time charge, the year-ago loss per share was $1, indicating a more modest improvement on a normalized basis. The company’s top line rose 11% year over year to $206.7 million, primarily driven by encouraging performance across several business segments. The company also showed improvement in cash generation metrics, highlighting better operating discipline.
However, long-term investors typically look beyond a single quarter’s results and instead focus on strong fundamentals. Let’s understand Tilray’s fundamentals to better analyze how to play the stock post-earnings.
Tilray’s Multi-Segment Model Continues to Drive Growth
While Tilray began as a cannabis-focused company, its strategic expansion into adjacent verticals is increasingly shaping its growth profile. Over the past few years, non-cannabis businesses — consisting of distribution, beverages and wellness — have accounted for a significant share of total revenues, reinforcing the company’s positioning as a diversified consumer platform.
The distribution segment remained the largest contributor, with revenues surging to a record $242.3 million in the first nine months of fiscal 2026, driven by strong momentum in Tilray Pharma, supported by improved product mix, higher-margin SKUs and expanding presence across European markets.
In contrast, the beverage segment faced near-term pressure, with revenues declining 15% year over year to $148.4 million so far in fiscal 2026. This weakness reflects not only softer industry trends but also Tilray’s ongoing portfolio rationalization and margin-focused initiatives under Project 420 — a plan to integrate its craft beer businesses and streamline operations. Notably, the company completed this program in the third quarter, delivering approximately $33 million in annualized cost savings and improving the segment’s cost structure.
Tilray also continues to expand its beverage ambitions through strategic initiatives. The recently announced acquisition of BrewDog and its partnership with Carlsberg are expected to significantly enhance scale, distribution capabilities and international reach, positioning the company to compete more effectively in the global craft beverage market.
Meanwhile, the wellness segment posted steady growth, supported by continued innovation and expansion in health-focused product categories.
Looking ahead, Tilray’s diversified model provides multiple avenues for growth. While the beverage segment is being reshaped through margin-focused actions, management noted these steps are aimed at resetting the business for more profitable long-term growth, with underlying fundamentals already improving. Strong performance in distribution and international cannabis, along with Project 420 savings and upcoming catalysts like BrewDog and Carlsberg, should support a more balanced growth trajectory.
Tilray’s Cannabis Business Gains Momentum Globally
Tilray’s cannabis operations span both recreational and medical markets, and performance in the first nine months of fiscal 2026 highlights improving traction across key regions.
In Canada, Tilray maintained its leadership position, with adult-use and medical cannabis revenues increasing 8% year over year, reaffirming its position as the country’s largest legal cannabis producer by revenues.
International cannabis has emerged as a key growth driver, with revenues rising 41% year over year to $57.7 million in the first nine months of fiscal 2026, fueled by robust demand and higher sales volumes across global medical markets. This strength reflects Tilray’s expanding presence in Europe, particularly in Germany, where the company continues to benefit from its vertically integrated model combining cultivation, distribution and pharmacy access.
Operationally, Tilray is enhancing its cultivation capabilities through modernization initiatives, including improved genetics, higher yields and AI-driven growing systems. These efforts are expected to support margin expansion and strengthen product consistency over time.
Intense Competition Remains a Key Overhang
Tilray operates in an increasingly crowded cannabis market, facing stiff competition from peers like Aurora Cannabis (ACB - Free Report) , Canopy Growth (CGC - Free Report) and Curaleaf Holdings (CURLF - Free Report) . These players are also expanding internationally and focusing on cost efficiencies, making differentiation more challenging.
As Tilray scales its presence in global medical cannabis markets, particularly in Europe, competitive intensity is likely to rise. Pricing pressure, supply expansion and aggressive market entry strategies from peers could limit margin expansion and market share gains over time.
TLRY Stock Performance & Valuation
Shares of Tilray Brands have plunged 32% year to date compared to the industry’s 14% decline.
Image Source: Zacks Investment Research
Estimates for TLRY’s loss per share for fiscal 2026 and 2027 have improved in the last 30 days.
Image Source: Zacks Investment Research
How to Play TLRY Stock?
With a Zacks Rank #3 (Hold), Tilray appears suited for a wait-and-watch approach at the current levels. While the company is witnessing strong momentum in its international cannabis and distribution businesses, continued pressure in the beverage segment continues to pressure overall performance. Additionally, although potential U.S. federal cannabis reforms could act as a meaningful long-term catalyst, the lack of clarity on timing limits near-term visibility. Investors may prefer to stay on the sidelines until clearer signs of sustained profitability and segmental stability emerge.
View the Zacks #1 Rank List
Image: Bigstock
Should Tilray Brands Be in Your Portfolio Post Q3 Earnings?
Key Takeaways
On Wednesday, Tilray Brands (TLRY - Free Report) reported mixed third-quarter results for fiscal 2026 (year ending May 2026), with revenues beating estimates but earnings missing expectations. Both numbers improved when compared to the year-ago quarter.
Tilray posted a loss per share of 24 cents, a 97% improvement from the year-ago quarter, which had been significantly impacted by a $699.2 million impairment charge. Excluding this one-time charge, the year-ago loss per share was $1, indicating a more modest improvement on a normalized basis. The company’s top line rose 11% year over year to $206.7 million, primarily driven by encouraging performance across several business segments. The company also showed improvement in cash generation metrics, highlighting better operating discipline.
However, long-term investors typically look beyond a single quarter’s results and instead focus on strong fundamentals. Let’s understand Tilray’s fundamentals to better analyze how to play the stock post-earnings.
Tilray’s Multi-Segment Model Continues to Drive Growth
While Tilray began as a cannabis-focused company, its strategic expansion into adjacent verticals is increasingly shaping its growth profile. Over the past few years, non-cannabis businesses — consisting of distribution, beverages and wellness — have accounted for a significant share of total revenues, reinforcing the company’s positioning as a diversified consumer platform.
The distribution segment remained the largest contributor, with revenues surging to a record $242.3 million in the first nine months of fiscal 2026, driven by strong momentum in Tilray Pharma, supported by improved product mix, higher-margin SKUs and expanding presence across European markets.
In contrast, the beverage segment faced near-term pressure, with revenues declining 15% year over year to $148.4 million so far in fiscal 2026. This weakness reflects not only softer industry trends but also Tilray’s ongoing portfolio rationalization and margin-focused initiatives under Project 420 — a plan to integrate its craft beer businesses and streamline operations. Notably, the company completed this program in the third quarter, delivering approximately $33 million in annualized cost savings and improving the segment’s cost structure.
Tilray also continues to expand its beverage ambitions through strategic initiatives. The recently announced acquisition of BrewDog and its partnership with Carlsberg are expected to significantly enhance scale, distribution capabilities and international reach, positioning the company to compete more effectively in the global craft beverage market.
Meanwhile, the wellness segment posted steady growth, supported by continued innovation and expansion in health-focused product categories.
Looking ahead, Tilray’s diversified model provides multiple avenues for growth. While the beverage segment is being reshaped through margin-focused actions, management noted these steps are aimed at resetting the business for more profitable long-term growth, with underlying fundamentals already improving. Strong performance in distribution and international cannabis, along with Project 420 savings and upcoming catalysts like BrewDog and Carlsberg, should support a more balanced growth trajectory.
Tilray’s Cannabis Business Gains Momentum Globally
Tilray’s cannabis operations span both recreational and medical markets, and performance in the first nine months of fiscal 2026 highlights improving traction across key regions.
In Canada, Tilray maintained its leadership position, with adult-use and medical cannabis revenues increasing 8% year over year, reaffirming its position as the country’s largest legal cannabis producer by revenues.
International cannabis has emerged as a key growth driver, with revenues rising 41% year over year to $57.7 million in the first nine months of fiscal 2026, fueled by robust demand and higher sales volumes across global medical markets. This strength reflects Tilray’s expanding presence in Europe, particularly in Germany, where the company continues to benefit from its vertically integrated model combining cultivation, distribution and pharmacy access.
Operationally, Tilray is enhancing its cultivation capabilities through modernization initiatives, including improved genetics, higher yields and AI-driven growing systems. These efforts are expected to support margin expansion and strengthen product consistency over time.
Intense Competition Remains a Key Overhang
Tilray operates in an increasingly crowded cannabis market, facing stiff competition from peers like Aurora Cannabis (ACB - Free Report) , Canopy Growth (CGC - Free Report) and Curaleaf Holdings (CURLF - Free Report) . These players are also expanding internationally and focusing on cost efficiencies, making differentiation more challenging.
As Tilray scales its presence in global medical cannabis markets, particularly in Europe, competitive intensity is likely to rise. Pricing pressure, supply expansion and aggressive market entry strategies from peers could limit margin expansion and market share gains over time.
TLRY Stock Performance & Valuation
Shares of Tilray Brands have plunged 32% year to date compared to the industry’s 14% decline.
Image Source: Zacks Investment Research
Estimates for TLRY’s loss per share for fiscal 2026 and 2027 have improved in the last 30 days.
Image Source: Zacks Investment Research
How to Play TLRY Stock?
With a Zacks Rank #3 (Hold), Tilray appears suited for a wait-and-watch approach at the current levels. While the company is witnessing strong momentum in its international cannabis and distribution businesses, continued pressure in the beverage segment continues to pressure overall performance. Additionally, although potential U.S. federal cannabis reforms could act as a meaningful long-term catalyst, the lack of clarity on timing limits near-term visibility. Investors may prefer to stay on the sidelines until clearer signs of sustained profitability and segmental stability emerge.
You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.